OPAL-HK
2015
Patiromer in Patients with CKD and Hyperkalaemia on RAAS Inhibitors
In 243 patients with CKD and hyperkalaemia on RAAS inhibitors, patiromer lowered serum potassium and recurrent hyperkalaemia compared with placebo withdrawal.
Result
- Absolute difference
- 45 points
- NNT
- 3
Absolute difference and NNT are derived from the event rates.
Also reported: Potassium −1.01 mmol/L (p<0.001);
- Subtopic
- Hyperkalaemia
- Design
- Single-blind, two-phase trial with randomised withdrawal
- Relevance
- Supporting: context rather than must-know.
- Cited in
- KDIGO 2024 CKD
- Source
- Weir MR, et al. N Engl J Med. 2015;372(3):211-221.doi 10.1056/NEJMoa1410853
Discussion & critique
Enabled continuation of RAAS inhibitors despite hyperkalaemia; led to approval of patiromer.